Trials / Terminated
TerminatedNCT05534789
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
Clinical Outcomes and Therapy Management Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1L) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Chart Review (RENALISTIC Study)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 106 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be: At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment
Conditions
Timeline
- Start date
- 2022-10-15
- Primary completion
- 2023-12-13
- Completion
- 2023-12-13
- First posted
- 2022-09-10
- Last updated
- 2025-01-20
- Results posted
- 2025-01-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05534789. Inclusion in this directory is not an endorsement.